What is the official website of Lilly Latam ?

The official website of Lilly Latam is http://www.lillylatam.com.

What is Lilly Latam's cybersecurity risk score?

Lilly Latam has an AI-generated cybersecurity risk score of 750 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Lilly Latam experienced?

According to Rankiteo, Lilly Latam currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Lilly Latam been affected by any supply chain cyber incidents ?

According to Rankiteo, Lilly Latam has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Lilly Latam have SOC 2 Type 1 certification ?

According to Rankiteo, Lilly Latam is not certified under SOC 2 Type 1.

Does Lilly Latam have SOC 2 Type 2 certification ?

According to Rankiteo, Lilly Latam does not hold a SOC 2 Type 2 certification.

Does Lilly Latam comply with GDPR ?

According to Rankiteo, Lilly Latam is not listed as GDPR compliant.

Does Lilly Latam have PCI DSS certification ?

According to Rankiteo, Lilly Latam does not currently maintain PCI DSS compliance.

Does Lilly Latam comply with HIPAA ?

According to Rankiteo, Lilly Latam is not compliant with HIPAA regulations.

Does Lilly Latam have ISO 27001 certification ?

According to Rankiteo,Lilly Latam is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Lilly Latam operate in ?

Lilly Latam operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Lilly Latam have ?

Lilly Latam employs approximately 7 people worldwide.

Does Lilly Latam own any subsidiaries ?

Lilly Latam presently has no subsidiaries across any sectors.

How many LinkedIn followers does Lilly Latam have ?

Lilly Latam's official LinkedIn profile has approximately 37,075 followers.

What is the NAICS classification code for Lilly Latam ?

Lilly Latam is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Lilly Latam have a Crunchbase profile ?

No, Lilly Latam does not have a profile on Crunchbase.

Does Lilly Latam have a LinkedIn profile ?

Yes, Lilly Latam maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/lilly-latam.

How many cybersecurity incidents has Lilly Latam experienced ?

As of September 30, 2026, Rankiteo reports that Lilly Latam has not experienced any cybersecurity incidents.

How many peer or competitor companies does Lilly Latam have ?

Lilly Latam has an estimated 5,771 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Lilly Latam

Boost Score +25 with badge (5 left)

750

/1000

Fair

775

/1000

Fair

Lilly Latam Vendor Cyber Rating & Cyber Score

lillylatam.com

Add Your Compliance Badge

Eli Lilly and Company une el cuidado de la salud con el descubrimiento para mejorar la vida de las personas en el mundo. Fuimos fundados hace más de un siglo por un hombre comprometido en crear medicinas de la más alta calidad para cubrir necesidades reales, y hoy mantenemos esa promesa en todo nuestro trabajo. Contamos con presencia en América Latina en 27 países a través de sus afiliadas (Argentina, Brasil, Chile, Colombia, Ecuador, México, Perú, y Venezuela). Esta página no está diseñada para discutir, comentar, debatir o prescribir, sobre los medicamentos desarrollados por Eli Lilly and Company u otras compañías farmacéuticas. Si los comentarios infringen esta cláusula o los “Términos de uso de Linkedin”, dicho contenido podrá ser

Lilly Latam

Lilly Latam CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Lilly Latam Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Lilly Latam

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Lilly Latam in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Lilly Latam in 2026.

Incident Types Lilly Latam vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Lilly Latam in 2026.

Incident History - Lilly Latam (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Lilly Latam Subsidiaries

Lilly Latam

Pharmaceutical Manufacturing

Website: http://www.lillylatam.com

Company Size: 501-1,000 employees

Eli Lilly and CompanyPharmaceutical Manufacturing

Lilly OncologyPharmaceutical Manufacturing

Lilly Medical USPharmaceutical Manufacturing

Lilly IndiaPharmaceutical Manufacturing

Lilly CareersPharmaceutical Manufacturing

Eli Lilly ItaliaPharmaceutical Manufacturing

Loading…

Lilly Latam Similar Companies

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Novartis

novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Servier

servier.com

Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Loading…

NEWS

Lilly Latam CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

August 23, 2025 03:36 AM

2025 SABRE Latin America Finalists

Finalists for the 2025 Latin America SABRE Awards, taking in Brazil on 16 September.

Read Article

March 03, 2025 08:00 AM

African drugmaker Aspen says new Latam and Eli Lilly portfolio boosting earnings

Aspen Pharmacare posted a 5% rise in half-year earnings on Monday and said it expects double-digit revenue and core profit growth in its...

Read Article

July 01, 2024 07:00 AM

Collaboration Can Improve Access to Innovative Treatments

Collaboration is required to address the health crisis caused by the growing rates of diabetes in Mexico, says Eli Lilly's Karla Alcazar.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-103047

SUMMARY

Improper neutralization of input during web page generation ('cross-site scripting') vulnerability in The Wikimedia Foundation Mediawiki - CentralAuth extension allows Stored XSS. This issue affects Mediawiki - CentralAuth extension: before 1.46.1, 1.45.5, 1.43.10.

Published

Date2026-09-29

Updated

Date2026-09-29

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-103046

SUMMARY

Improper neutralization of input during web page generation ('cross-site scripting') vulnerability in Wikimedia Foundation MediaWiki - WikiLambda extension allows Stored XSS. This issue affects MediaWiki - WikiLambda extension: before 1.46.1.

Published

Date2026-09-29

Updated

Date2026-09-29

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-103045

SUMMARY

Improper neutralization of input during web page generation ('cross-site scripting') vulnerability in The Wikimedia Foundation Mediawiki - Refreshed skin allows Stored XSS. This issue affects Mediawiki - Refreshed skin: before 1.46.1, 1.45.5, 1.43.10.

Published

Date2026-09-29

Updated

Date2026-09-29

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-103044

SUMMARY

XML injection (aka blind XPath injection) vulnerability in The Wikimedia Foundation Mediawiki - EasyTimeline extension allows XML Injection. This issue affects Mediawiki - EasyTimeline extension: before 1.46.1, 1.45.5, 1.43.10.

Published

Date2026-09-29

Updated

Date2026-09-29

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-103043

SUMMARY

anchorme through 3.0.8 contains a regular expression denial of service vulnerability in the IPv6 host extraction regex due to catastrophic backtracking. Attackers can supply specially crafted input strings with repeated patterns to cause exponential regex engine backtracking, blocking the Node.js event loop and denying service to other requests.

Published

Date2026-09-29

Updated

Date2026-09-29

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Lilly Latam Vendor Cyber Rating & Cyber Score

Lilly Latam A.I CyberSecurity Scoring

Lilly Latam CyberSecurity News & History

Lilly Latam Company Scoring based on AI Models